Programs & Research

Our pipeline diversification offers opportunities to advance novel treatments across therapeutic areas and mechanisms of action

Abstract swirl background
Abstract swirl background

MM120 | LSD D-tartrate

Lead Candidate with Evidence Across Multiple Therapeutic Areas

Extensive evidence of clinical benefit and mechanistic rationale in psychiatry, pain and substance use disorders

Psychiatry - Rapid & sustained benefit after acute dosing. 3x effect size compared to available affective disorder therapies. Safety & Pharmacology - 10,000+ patients treated in clinical trials. Well Characterized tolerability, pharmacokinetics and pharmacodynamics. Pain - Novel MOA that targets neurobiology of chronic pain. 2nd generation delivery opportunity to enhance access and scalability

Learn more about the study at our Clinical Trials page.

MM402 | R(-)-MDMA

Clinical Data Support Opportunity in ASD

Pilot clinical trial results of MDMA demonstrate acute and durable positive effects on social functioning in ASD population

Translational preclinical data suggest that R(-)-MDMA may have: Strong prosocial effects, Less stimulant activity compared to MDMA, Superior safety and tolerability profile, Potential to be administered in standard dosing regimen

1. Pitts 2018; Psychopharmacology; 235.

2. Curry 2018; Neuropharmacology; 128.

Translational preclinical data suggest that R(-)-MDMA may have:

  • Strong prosocial effects
  • Less stimulant activity compared to MDMA
  • Superior safety and tolerability profile
  • Potential to be administered in standard dosing regimen

Relevant References, Publications and Scientific Literature

 

NOTE: Information above was obtained form publicly available sources and is presented only for purposes of providing a general overview of information on investigational products and uses that have not been approved by the U.S. Food and Drug Administration.